From European introduction to U.S. launch, MAMMOKNIFE enters the next phase of its journey.
Currently in development. MAMMOKNIFE has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for commercial use.
Following its European debut at ESTRO 2026 in Stockholm, MAMMOKNIFE arrived in Boston for its official U.S. launch at ASTRO 2026.
The American Society for Radiation Oncology’s 68th Annual Meeting brought the global radiation oncology community together in Boston from September 26–30.
More than 10,000 oncology professionals. Three days. One stage for the U.S. launch of MAMMOKNIFE.
A bigger stage. A broader conversation.
At ASTRO, we introduced MAMMOKNIFE to the U.S. radiation oncology market through a 900 square foot exhibit designed to put the technology front and center.
The response was immediate.
From interest to collaboration
ASTRO opened conversations with leading academic and clinical institutions about the future of MAMMOKNIFE and the development of its clinical consortium.
The initial process is now underway, with strong interest from leading U.S. institutions in helping shape the next phase of the platform.
These discussions are focused on more than evaluating the technology. They are exploring how clinical expertise can contribute to treatment planning, dosimetric analysis, study design, patient selection and the development of the evidence needed to bring a new approach to breast radiotherapy forward.
ASTRO transformed initial market interest into the beginnings of clinical collaboration.
The response extends beyond the clinic
The conversations also extended across the broader radiation oncology ecosystem.
It demonstrated that the opportunity around dedicated breast radiotherapy is not limited to a single clinical specialty. It touches clinical care, physics, technology, infrastructure and access.
That broader interest is an important part of building a new category.
The next phase
ESTRO introduced MAMMOKNIFE to Europe.
ASTRO introduced MAMMOKNIFE to the United States.
Together, these milestones represent a transition from introducing the concept to building the network around it.
The next phase is about collaboration, evidence and execution.
Important Notice: MAMMOKNIFE is currently in development. The device has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for commercial use.